Non-Interventional Study on Safety of Liraglutide in Subjects With Type 2 Diabetes

• Status: Completed
• Trial end date: 2013-07-26
• Target enrollment: 0
• Participant gender: All

Summary

This trial is conducted in Asia. The aim of this trial is to investigate the safety profile of liraglutide under normal conditions of use.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Novo Nordisk A/S
• Treatments: Liraglutide

Criteria

Inclusion Criteria:

• Subjects with type 2 diabetes mellitus, including newly-diagnosed subjects or those already receiving other anti-diabetic medications including GLP-1 analogues other than Liraglutide, who require treatment with liraglutide according to the clinical judgment of their treating physician

• Subjects who are capable of giving study-specific signed informed consent before any collection of information

Exclusion Criteria:

• Subjects with type 1 diabetes

• Subjects who are or have previously been on liraglutide

• Subjects who are participating in another clinical trial

• Subjects with a hypersensitivity to liraglutide or to any of the excipients (Disodium phosphate dihydrate, propylene glycol, phenol, water for injections)

• Subjects who are pregnant, breast feeding or have the intention of becoming pregnant within the following 6 months